Mylan Hit With $69.2M In Treble Damages

Law360, New York (January 24, 2008, 12:00 AM EST) -- Blue Cross Blue Shield of Massachusetts and three other health insurance firms that opted out of a $35 million class-action settlement against Mylan Laboratories Inc. to pursue their own antitrust allegations have won a whopping $69.2 million award in treble damages.

The insurers alleged that the generic drug maker tied up the market for two anti-anxiety drugs, lorazepam and clorazepate, and inflated the prices.

Judge Thomas F. Hogan of the U.S. District Court for the District of Columbia on Thursday granted the indirect purchasers’ motions for...
To view the full article, register now.